Experience a different kind of PBM

We’re your trusted, transparent partner that’s reimagining pharmacy solutions to deliver value back to those we serve and transforming our industry for the better.

Get to know us

Transforming the PBM model

Turning barriers into breakthroughs. Questions into trust. Fears into cures. See how we're reimagining pharmacy solutions.

Our solutions

Our 7,000+ dedicated employees are committed to challenging norms and curating innovative pharmacy solutions that simplify the complex and provide exceptional experiences for millions of people across the nation.

Save

Make medication more affordable

Explore now

Simplify

Deliver an easy, transparent experience

See how

Support

Help people achieve better health

Learn more

How we're different

Prime travels a different path, creating a new standard for the industry based on four key areas of distinction.

Truly transparent and conflict free

We don’t steer people to our pharmacies or pursue the highest margins. Instead, we demonstrate true transparency to do what’s right for our customers and their members, passing value back to those we serve.

Holistic specialty expertise

With unmatched experience, we take a comprehensive approach to specialty drugs. We manage whole-person health and look at insights across both the pharmacy and medical benefit.

Modern technology

With exclusive access to the most modern, connected and intuitive pharmacy platform, we’re accelerating innovation to meet the moment for our customers.

Purpose beyond profits

As a privately held company owned by mission-driven partners, we aren’t just about making money, and we’re not distracted by short-term priorities. Instead, we’re creating transformative impact with the best long-term solutions.

What's trending?

From breaking news to insightful stories and event highlights, we've got every angle covered. Whether it's the most recent industry trends or expert perspectives, you'll find it all right here — because, at Prime, we have our finger on the pulse of pharmacy.

What you need to know about a potential new indication of a GLP-1 drug for MASH therapy

Novo Nordisk’s semaglutide (Wegovy) is expected to receive a U.S. Food and Drug Administration (FDA) decision for treating metabolic dysfunction-associated steatohepatitis (MASH), potentially the first GLP-1 approved for this indication

One drug's evolving role in treating thyroid eye disease

Discover how emerging strategies for teprotumumab-trbw (Tepezza) are reshaping thyroid eye disease treatment — from first-line therapy potential to smart retreatment decisions.

Paws-itive change: Can Do Canines empowers individuals with disabilities

Minnesota-based organization, recipient of a 2024 Prime Together Foundation grant, trains service dogs using volunteers — including incarcerated individuals.